Tag: Chronic spontaneous urticaria

Xolair (omalizumab) is a biologic medication used to treat conditions like moderate-to-severe persistent asthma, which affects millions worldwide [1.6.2]. A common question for patients is, **how long before Xolair is out of your system?** Due to its long half-life, the process is gradual.

While omalizumab proves effective for many patients with chronic spontaneous urticaria and severe allergic asthma, a significant percentage of individuals experience a poor or non-existent response. Identifying what is a poor predictor for response to omalizumab is crucial for clinicians to manage patient expectations and optimize therapeutic outcomes.

The average elimination half-life of omalizumab is approximately 26 days in patients with asthma and 24 days in patients with chronic spontaneous urticaria [1.2.1, 1.2.5]. This extended half-life allows for infrequent dosing, typically every two or four weeks [1.2.4].